PCI Pharma Services
PCI Pharma Services, headquartered in Philadelphia, is a leading biotherapy manufacturing company with over 50 years of industry experience. The company specializes in offering integrated end-to-end drug development, manufacturing, and packaging solutions tailored to the complex needs of biopharmaceutical clients. Over the past five years, PCI has successfully launched more than 450 products, establishing a strong presence in the global biotherapy market. With 38 sites across seven countries and a workforce of more than 7,500 employees, PCI is committed to expanding its capabilities, including sterile fill-finish injectables and high-potent manufacturing. Recent strategic investments from Bain Capital, Kohlberg, and Mubadala aim to support PCI’s growth, innovation, and global reach, strengthening its role in advancing pharmaceutical supply chain infrastructure and better patient outcomes worldwide.
News Summary
PCI Pharma Services, a leading biotherapy manufacturing firm in Philadelphia, has received a strategic investment co-led by Bain Capital to enhance its capabilities in the biopharmaceutical sector. This funding aims to accelerate PCI’s growth as a global Contract Development and Manufacturing Organization (CDMO) and support its commitment to innovation in drug development and manufacturing. With over 450 products launched in the last five years and a focus on expanding sterile manufacturing capabilities, PCI is positioned to meet evolving market demands and strengthen the U.S. pharmaceutical supply chain.
Philadelphia – PCI Pharma Services, a leading biotherapy manufacturing firm based in Philadelphia, has secured a significant strategic investment aimed at bolstering its growth in the biopharmaceutical sector. The investment is co-led by Bain Capital, in collaboration with existing investors Kohlberg and Mubadala Investment Company.
While the financial specifics of the transaction remain undisclosed, this infusion of capital is expected to enhance PCI’s capabilities in the biotherapy market and accelerate its journey toward redefining itself as a global Contract Development and Manufacturing Organization (CDMO).
PCI Pharma Services has established an impressive track record, successfully launching more than 450 products over the last five years and leveraging over 50 years of industry experience in pharmaceutical services. The company offers integrated end-to-end drug development, manufacturing, and packaging capabilities, catering to the complex needs of its biopharmaceutical customers.
The involvement of Bain Capital marks a new chapter in PCI’s growth strategy. With the backing of their investment, PCI aims to bolster its capacity to meet evolving market demands. In addition, Partners Group will maintain its support with a minority investment in the company.
PCI’s management team, under the leadership of CEO Salim Haffar, is focused on enhancing customer experience and ensuring thorough integrated supply chain solutions. This strategic investment is also designed to foster both organic and inorganic growth initiatives, which will include the expansion of services and widening geographic reach.
As part of its future growth strategy, PCI plans to emphasize the development of sterile fill-finish injectables and high-potent specialized manufacturing capabilities. This move is aligned with the company’s goal to strengthen the U.S. pharmaceutical manufacturing and supply chain infrastructure, ensuring that they meet both domestic and global demands.
Matt Jennings, chairman of PCI and an operating partner at Kohlberg, noted the effective collaboration between PCI’s dedicated management team and the expertise of seasoned investors, which is crucial in supporting the company’s growth ambitions. Bain Capital has reaffirmed its commitment to innovation and excellence within the advanced pharmaceutical services sector to ultimately improve patient outcomes.
Currently, PCI operates 38 sites across seven countries and employs more than 7,500 individuals. This broad operational footprint underscores the company’s significant role in the global biotherapy landscape. As PCI continues on its trajectory of growth with the backing of its strategic investors, it will be crucial in navigating the challenges and opportunities within the pharmaceutical industry.
In terms of financial advisement, Jefferies LLC acted as the lead financial advisor to PCI, with Moelis & Company LLC serving as co-advisor. For Bain Capital, financial guidance was provided by Morgan Stanley & Co. LLC and BofA Securities, while Citi offered advisory services for Mubadala. The legal aspects of the transaction were managed by several prominent law firms, with Paul, Weiss, Rifkind, Wharton & Garrison LLP representing PCI and Kohlberg.
As the biopharmaceutical landscape evolves, investments such as this are critical in ensuring that manufacturing and supply chain capabilities keep pace with industry demands, ultimately benefiting patients through improved access to innovative therapies.
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- Penn Biz Report
- Wikipedia: Biopharmaceutical
- Business Wire
- Google Search: Pharmaceutical investment in Philadelphia
- Philadelphia Inquirer
- Google Scholar: PCI Pharma Services
- Fierce Pharma
- Encyclopedia Britannica: Contract Development and Manufacturing Organization
- City & State PA
- Google News: biopharmaceutical investments
